EXAS Stock Overview
Provides cancer screening and diagnostic test products in the United States and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 6/6 |
| Future Growth | 4/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Exact Sciences Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$56.36 |
| 52 Week High | US$86.01 |
| 52 Week Low | US$40.62 |
| Beta | 1.22 |
| 11 Month Change | 19.79% |
| 3 Month Change | 8.49% |
| 1 Year Change | -33.24% |
| 33 Year Change | -39.26% |
| 5 Year Change | -52.73% |
| Change since IPO | 282.10% |
Recent News & Updates
Recent updates
Exact Sciences Corporation's (NASDAQ:EXAS) Share Price Boosted 27% But Its Business Prospects Need A Lift Too
Aug 14
Exact Sciences: Still No Reason To Own
Jun 11Revenues Working Against Exact Sciences Corporation's (NASDAQ:EXAS) Share Price Following 27% Dive
Jun 02An Intrinsic Calculation For Exact Sciences Corporation (NASDAQ:EXAS) Suggests It's 46% Undervalued
Feb 23Investors Don't See Light At End Of Exact Sciences Corporation's (NASDAQ:EXAS) Tunnel
Jan 08Exact Sciences Corporation (NASDAQ:EXAS) Shares Could Be 42% Below Their Intrinsic Value Estimate
Nov 15Exact Sciences (NASDAQ:EXAS) Is Carrying A Fair Bit Of Debt
Oct 04An Intrinsic Calculation For Exact Sciences Corporation (NASDAQ:EXAS) Suggests It's 44% Undervalued
Aug 14Here's Why Exact Sciences (NASDAQ:EXAS) Can Afford Some Debt
Jun 15Calculating The Fair Value Of Exact Sciences Corporation (NASDAQ:EXAS)
Apr 26We Think Exact Sciences (NASDAQ:EXAS) Has A Fair Chunk Of Debt
Feb 23An Intrinsic Calculation For Exact Sciences Corporation (NASDAQ:EXAS) Suggests It's 45% Undervalued
Jan 10Shareholder Returns
| EXAS | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 0.7% | 3.8% | 4.5% |
| 1Y | -33.2% | 12.6% | 21.7% |
Return vs Industry: EXAS underperformed the US Biotechs industry which returned 12.6% over the past year.
Return vs Market: EXAS underperformed the US Market which returned 21.7% over the past year.
Price Volatility
| EXAS volatility | |
|---|---|
| EXAS Average Weekly Movement | 10.2% |
| Biotechs Industry Average Movement | 10.6% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 14.9% |
| 10% least volatile stocks in US Market | 3.2% |
Stable Share Price: EXAS's share price has been volatile over the past 3 months.
Volatility Over Time: EXAS's weekly volatility (10%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1995 | 6,550 | Kevin Conroy | www.exactsciences.com |
Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services.
Exact Sciences Corporation Fundamentals Summary
| EXAS fundamental statistics | |
|---|---|
| Market cap | US$10.87b |
| Earnings (TTM) | -US$175.01m |
| Revenue (TTM) | US$2.61b |
4.0x
P/S Ratio-59.5x
P/E RatioIs EXAS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| EXAS income statement (TTM) | |
|---|---|
| Revenue | US$2.61b |
| Cost of Revenue | US$700.34m |
| Gross Profit | US$1.91b |
| Other Expenses | US$2.09b |
| Earnings | -US$175.01m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.95 |
| Gross Margin | 73.19% |
| Net Profit Margin | -6.70% |
| Debt/Equity Ratio | 80.4% |
How did EXAS perform over the long term?
See historical performance and comparison